Ontology highlight
ABSTRACT:
SUBMITTER: Kahraman DC
PROVIDER: S-EPMC6072489 | biostudies-literature | 2017 Jan
REPOSITORIES: biostudies-literature
Kahraman Deniz Cansen DC Hanquet Gilles G Jeanmart Loïc L Lanners Steve S Šramel Peter P Boháč Andrej A Cetin-Atalay Rengul R
MedChemComm 20161007 1
Bioactivities of quinoides <b>1-5</b> and VEGFR2 TKIs <b>6-10</b> in hepatocellular cancer (HCC) and cancer stem cells (HCSCs) were studied. The compounds exhibited IC<sub>50</sub> values in μM concentrations in HCC cells. Quinoide <b>3</b> was able to eradicate cancer stem cells, similar to the action of the stem cell inhibitor <b>DAPT</b>. However, the more cytotoxic VEFGR TKIs (IC<sub>50</sub>: 0.4-3.0 μM) including sorafenib, which is the only FDA approved drug for the treatment of HCC, enri ...[more]